MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
12.85
+0.44
+3.55%
Pre Market: 12.97 +0.12 +0.97% 04:02 03/31 EDT
OPEN
12.45
PREV CLOSE
12.41
HIGH
13.02
LOW
12.27
VOLUME
22
TURNOVER
0
52 WEEK HIGH
20.76
52 WEEK LOW
6.68
MARKET CAP
1.98B
P/E (TTM)
-32.7639
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADPT last week (0323-0327)?
Weekly Report · 23h ago
A Look At Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness
Simply Wall St · 3d ago
Adaptive Biotechnologies President and COO Julie Rubinstein; disposes of common shares worth $796,516
Reuters · 4d ago
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year
The Motley Fool · 4d ago
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price
The Motley Fool · 4d ago
Adaptive Biotechnologies launches clonoSEQ MRD test for blood cancers
Reuters · 6d ago
Adaptive Biotechnologies President and COO Julie Rubinstein disposes of USD 765,393 in common shares
Reuters · 03/23 23:19
Weekly Report: what happened at ADPT last week (0316-0320)?
Weekly Report · 03/23 09:09
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.